Robert N. Cavanaugh, President of Accolade, Inc. (NASDAQ:ACCD), reported the sale of 214 shares of common stock valued at approximately $778. The shares were sold at an average price of $3.638 per share. This transaction, which took place on November 12, was conducted to cover tax withholding obligations related to the vesting of restricted stock units (RSUs).
Additionally, Cavanaugh executed a transaction on November 11, where he acquired 711 shares of common stock through the conversion of RSUs. This acquisition did not involve any cash exchange as each RSU converted into one share of common stock. Following these transactions, Cavanaugh holds 199,146 shares in direct ownership.
In other recent news, Accolade Inc (NASDAQ:ACCD). posted robust second-quarter results for 2025, with revenues totaling $106.4 million, surpassing expectations. The company also exceeded its adjusted EBITDA guidance and confirmed its fiscal year 2025 revenue guidance between $460 million to $475 million, forecasting a positive adjusted EBITDA of $15 million to $20 million. Wells Fargo (NYSE:WFC), Stephens, Canaccord Genuity, Truist Securities, and BofA Securities have all revised their price targets for Accolade, with Wells Fargo and Stephens maintaining an Equal Weight and Overweight rating respectively, and the rest maintaining Buy ratings. This comes amid concerns over delayed deal closures, which may affect Accolade's revenue growth into Fiscal Year 26.
Despite these concerns, analysts suggest that with moderate growth in Annual Contract Value, the company's revenue targets for FY26 are achievable. The management at Accolade remains optimistic about a strong pipeline diversified across employers, health plans, and government segments. However, slower revenue growth is anticipated in fiscal year 2026 due to staggered launches. These are the recent developments for Accolade Inc., a healthcare solutions provider.
InvestingPro Insights
While Robert N. Cavanaugh's recent stock transactions provide insight into insider activity at Accolade, Inc. (NASDAQ:ACCD), a broader look at the company's financial metrics offers additional context for investors. According to InvestingPro data, Accolade's market capitalization stands at $301.21 million, reflecting its current position in the healthcare technology sector.
The company's revenue growth is noteworthy, with a 16.04% increase over the last twelve months as of Q2 2025, reaching $441.03 million. This growth trajectory is complemented by a gross profit margin of 48.24%, indicating Accolade's ability to maintain pricing power in its service offerings.
However, InvestingPro Tips highlight some challenges. Analysts do not anticipate the company will be profitable this year, which aligns with the reported operating income margin of -21.24%. Additionally, the stock has taken a significant hit over the last six months, with a price total return of -48.54% during that period.
On a positive note, Accolade operates with a moderate level of debt and its liquid assets exceed short-term obligations, suggesting a stable financial foundation despite current profitability challenges. These insights are part of a larger set of 10 tips available on InvestingPro, offering subscribers a more comprehensive analysis of Accolade's financial health and market position.
As the healthcare technology landscape evolves, investors may find value in monitoring Accolade's progress towards profitability and its ability to leverage its growing revenue base. The InvestingPro platform provides additional metrics and analysis that could be crucial for making informed investment decisions in this dynamic sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.